Aspirin versus P2Y12 inhibitor–based monotherapy after percutaneous coronary intervention - 26/11/20
Doi : 10.1016/j.ahj.2020.09.002
Rahul Choudhary, DM ⁎ 
, Vimla Kumari, MS
, Vimla Kumari, MS Department of Cardiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
⁎Reprint requests: Rahul Choudhary, Department of Cardiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India 342005.Department of CardiologyAll India Institute of Medical SciencesJodhpurRajasthan342005India
Le texte complet de cet article est disponible en PDF.
| Disclosure/conflict of interest statement • None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper. • It is to specifically state that “no competing interests are at stake and there is no conflict of interest” with other people or organizations that could inappropriately influence or bias the content of the paper. There is nothing to disclose for both authors. |
|
| Aspirin versus P2Y12 inhibitor–based monotherapy—Optimal duration and ideal agent |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 230
P. 99 - décembre 2020 Retour au numéro
Article précédent
- Cardiac intensive care unit during the coronavirus disease 2019 surge
- Boban Thomas, Imad Hassan
- Choosing between aspirin or P2Y12 monotherapy after short course of DAPT
- Toshiki Kuno, Hiroki Ueyama, Hisato Takagi, Sripal Bangalore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?